Final Programme - iuphar

More documents

Recommendations

Info

380 Index Name Paper ref. Name Paper ref. Zare, A Tue 017 Zarkovski, A Thu 409 Zarrindast, M Wed 027, Wed 437 Zarrindast, M-R Mon 437 Zarros, A Thu 431, Tue 381 Zasadny, K Tue 372 Zastre, J Mon 070 Zaychenko, GV Tue 218, Thu 382 Zdarova-Karasova, J Tue 343, Mon 075 Zebedin-Brandl, E Mon 217 Zebuhr, L Tue 214 Zegarra, C Mon 451 Zehender, M Wed 099 Zeilhofer, HU FC03.3.3 Zeng, Y Tue 094 Zermani, R Mon 338 Zerpa, H Tue 362 Zezelic, S Mon 370 Zgheib, N FC01.3.4 Zhai, Q-W Thu 210 Zhan, Q Tue 145 Zhan, RX Wed 291 Zhanataev, AK Tue 165 Zhang, B Thu 276 Zhang, B-R Mon 265 Zhang, C Tue 285 Zhang, D Tue 295, Tue 153, FC10.1.5 Zhang, D Tue 296 Zhang, D Tue 166 Zhang, F Thu 186 Zhang, G Mon 469, Wed 122 Zhang, G-R Mon 470 Zhang, G Tue 155 Zhang, H Thu 371, Mon 467, Mon 092, Thu 384, Tue 440, Thu 372, Wed 322 Zhang, H-L Thu 292, Wed 259 Zhang, H-N FC09.5.6 Zhang, J Wed 331, Wed 242, Thu 383, Mon 035, Mon 329, Mon 352, Tue 075, Thu 372, Thu 277, Thu 093 Zhang, JQ Thu 295 Zhang, K-Z Mon 265 Zhang, L Thu 370, Mon 265, Tue 083, Thu 196, Tue 378, Thu 378, Thu 384 Zhang, M FC12.4.5, Mon 265, Thu 172 Zhang, P FC02.3.5 Zhang, Q FC16.3.1, Tue 188, Tue 189, Thu 390, Wed 379 Zhang, R Tue 299, Wed 254 Zhang, SF Wed 039 Zhang, S-Q FC14.5.4 Zhang, T Tue 297 Zhang, T Thu 019, Thu 020 Zhang, W Tue 185, Tue 440 Zhang, W-C Mon 421 Zhang, W-K Thu 375 Zhang, X Thu 445, Thu 089, W33.2, Tue 076 Zhang, X-H W04.1.2 Zhang, X-Q Mon 082, Thu 385 Zhang, Y Wed 402, Thu 432, Tue 117, Thu 369, Thu 306, Tue 285, Thu 021, Tue 185, Tue 292, Thu 368, Wed 213, Wed 033, Tue 403, Tue 298 Zhang, Y-H Mon 082, Thu 385 Zhang, Y Tue 075 Zhang, YL Mon 053 Zhang, Y-H Thu 386 Zhang, Y-X FC16.3.1, Wed 379, Mon 470 Zhang, Z Tue 076 Zhang, Z-Q FC14.5.4 Zhao, J-N FC16.5.5 Zhao, M Tue 159, Thu 277, Thu 292, Wed 259 Zhao, P Tue 425, Tue 371 Zhao, W FC10.5.5 Zhao, X Mon 082 Zhao, Y FC02.1.2, Wed 402, Tue 130, Tue 285 Zhao, YB Mon 032 Zhao, Z Wed 378, Tue 181, Tue 076 Zhdanov, V Tue 167 Zheng, J Tue 299, Zheng, J-P Tue 185 Zheng, J-Q Thu 171 Zheng, R Tue 296, Tue 295 Zheng, S-Z Tue 400 Zheng, X Thu 388, FC12.2.5 Zheng, Y Thu 299 Zherdev, V Tue 150 Zhong, B Thu 298 Zhong, H Mon 046 Zhong, W Tue 152 Zhorov, BS FC12.5.5 Zhou, C Tue 155 Zhou, F Tue 440 Zhou, H Tue 229, Tue 299, Thu 377 Zhou, J-C Mon 031 Zhou, J Thu 387 Zhou, L Thu 388 Zhou, N Thu 372 Zhou, PXL Thu 381, Thu 389 Zhou, P-L Tue 083 Zhou, S-P Mon 470 Zhou, W Wed 402 Zhou, W Thu 432 Zhou, W-X FC16.3.1, Wed 379, Mon 470 Zhou, Y FC12.5.4 Zhu, A Tue 372 Zhu, B Tue 156 Zhu, C Tue 155 Zhu, H Tue 163 Zhu, J Wed 093 Zhu, L Mon 414, Tue 173, Tue 325, Mon 408, Wed 267 Zhu, Q Wed 362, Mon 323 Zhu, R Wed 076 Zhu, W Thu 445, Thu 089 Zhu, X Tue 138, Tue 094 Zhu, XX Mon 469 Zhu, Y Wed 242 Zhu, Z Tue 384, Thu 390, Tue 076 Zhukov, V Wed 188
Name Paper ref. Name Paper ref. Zhuravlev, YN FC16.5.1 Zia, M Thu 391, Thu 392 Ziaurrahman, S Tue 119 Zibar, L Tue 121 Ziberna, L Thu 293, Thu 359 Ziche, M Wed 243 Zidariè, M Wed 153 Zidek, Z Wed 118 Zídek, Z Wed 386, Tue 300 Ziganshin, AU Thu 096 Ziganshina, LE Thu 096 Ziogas, J Wed 288, Wed 289, Mon 214, Thu 393 Zitman, FG Wed 432, Tue 096 Zolfagharpour, A Thu 209 Zolotarev, V W02.1.2 Zolotov, N Mon 462 Zong, S FC03.4.5 Zoric, Z Thu 436, Mon 446 Zorina, L Wed 314 Zou, F Mon 210 Zou, Q Thu 294 Zou, X Wed 150 Zoulova, J Tue 342, Thu 168 Zsifkovits, C Wed 016 Zubata, I Tue 342 Zügel, S Tue 462 Zúñiga, C Wed 217 Zuo, P Mon 465, Wed 429 Zupkó, I Tue 130, Tue 442, Thu 308 Zusmanovich, M Mon 228 Zvejniece, L Thu 189 Zwane, N Tue 001 Zwisler, ST FC13.5.5 Zwykiel, S Wed 056 Zychar, BC Wed 333, Wed 334 Zygmunt, M Tue 039 Zygmunt, P FC09.4.5 Index 381
Page 1:
of basic and clinical pharmacology
Page 4 and 5:
Congress patron 2 HRH Crown Princes
Page 6 and 7:
Congress President Kim Brøsen Secr
Page 8 and 9:
General information Registration &
Page 10 and 11:
Banks, currency & credit cards The
Page 12 and 13:
Information to presenters ■ The a
Page 14 and 15:
Hotel Bella Center Copenhagen Groun
Page 16 and 17:
Programme at a glance Time Hall A2
Page 18 and 19:
16 General events General events Op
Page 20 and 21:
Programme outline Plenary lectures
Page 22 and 23:
FC10 Drugs for half the world: Paed
Page 24 and 25:
Tue 12:45 W13 Workshop: Novel perip
Page 26 and 27:
W01 Pharmacology of adrenoceptors:
Page 28 and 29:
W02 Symposium on advances in GI pha
Page 30 and 31:
W04 Symposium: Antioxidants as ther
Page 32 and 33:
Plenary lectures PL01 Plenary lectu
Page 34 and 35:
FC02 Transmembrane transport: Persp
Page 36 and 37:
FC04 Pharmacoepidemiology, current
Page 38 and 39:
FC06 The heart gone wrong: Stabiliz
Page 40 and 41:
FC09 Inflammation and immunopharmac
Page 42 and 43:
Page 44 and 45:
SS01 Sponsored symposium Sponsored
Page 46 and 47:
W06 Workshop. Effect of disease on
Page 48 and 49:
W08 Workshop. Identifying targets f
Page 50 and 51:
W10 Workshop. Innovative Medicines
Page 52 and 53:
FC01 Clinical pharmacology in the e
Page 54 and 55:
FC03 Ion channels in analgesia and
Page 56 and 57:
FC05 Translational science in the m
Page 58 and 59:
Page 60 and 61:
FC08 Development in the treatment o
Page 62 and 63:
Plenary lectures PL04 Plenary lectu
Page 64 and 65:
Page 66 and 67:
Page 68 and 69:
Page 70 and 71:
FC07 Simulation and data modelling
Page 72 and 73:
Page 74 and 75:
W12 Workshop. Experimental pain met
Page 76 and 77:
W14 Workshop. Translating the human
Page 78 and 79:
W15 Workshop. The IUPHAR initiative
Page 80 and 81:
W17 Workshop. Standards for PhD Edu
Page 82 and 83:
W19 Workshop. Influence of degenera
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
FC08 Development in the treatment o
Page 92 and 93:
PL10 ASPET Plenary Lecture Chair: T
Page 94 and 95:
Page 96 and 97:
FC12 Ion channelopathies: New windo
Page 98 and 99:
FC14 Addiction and doping: Neurobio
Page 100 and 101:
FC17 New approaches and targets in
Page 102 and 103:
W04 Symposium: Antioxidants as ther
Page 104 and 105:
W21 Workshop. Inflammation - here,
Page 106 and 107:
W23 Workshop. Applying pharmacogeno
Page 108 and 109:
W25 Workshop. High science in the l
Page 110 and 111:
W27 Workshop. Approaches to medicin
Page 112 and 113:
FC11 G protein-coupled 7TM receptor
Page 114 and 115:
FC13 Maximising benefits and minimi
Page 116 and 117:
FC15 Endothelium in Health and dise
Page 118 and 119:
Page 120 and 121:
FC18 Nuclear receptor targets for t
Page 122 and 123:
PL16 Plenary Lecture Supported by a
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
FC15 Endothelium in Health and dise
Page 130 and 131:
Page 132 and 133:
W28 Workshop. The Boehringer-Ingelh
Page 134 and 135:
W30 Workshop. Is eNOS still a valid
Page 136 and 137:
W32 Workshop. The good, the bad and
Page 138 and 139:
W34 Workshop. State-of-the-art of b
Page 140 and 141:
FC10 Drugs for half the world: Pedi
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
FC16 Natural products: Past and fut
Page 148 and 149:
Page 150 and 151:
PL22 Plenary Lecture Chair: Zhi-Bin
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
FC15 Endothelium in health and dise
Page 158 and 159:
Page 160 and 161:
158
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
W12 Experimental pain methods in de
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
FC06 The heart gone wrong; stabiliz
Page 180 and 181:
Page 182 and 183:
FC08 Developments in the treatment
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
W03 Targeting TRP channels for pain
Page 196 and 197:
W19 Influence of degeneration and r
Page 198 and 199:
W19 Influence of degeneration and r
Page 200 and 201:
W20 Pharmacology education for a su
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
FC06 The heart gone wrong; stabiliz
Page 216 and 217:
Page 218 and 219:
FC08 Developments in the treatment
Page 220 and 221:
Page 222 and 223:
Page 224 and 225:
Page 226 and 227:
Page 228 and 229:
Page 230 and 231:
FC19 General session Tue 361 Analge
Page 232 and 233:
FC19 General session - Biologics Tu
Page 234 and 235:
FC19 General session - Haematology
Page 236 and 237:
FC19 General session - oncology Tue
Page 238 and 239:
FC19 General session - oncology Tue
Page 240 and 241:
FC19 General session - Toxicology T
Page 242 and 243:
Page 244 and 245:
W11 New opportunities in the pharma
Page 246 and 247:
W23 Applying pharmacogenomics (PGX)
Page 248 and 249:
Page 250 and 251:
Page 252 and 253:
Page 254 and 255:
Page 256 and 257:
Page 258 and 259:
Page 260 and 261:
Page 262 and 263:
Page 264 and 265:
Page 266 and 267:
Page 268 and 269:
W30 Is eNOS Still a valid therapeut
Page 270 and 271:
Page 272 and 273:
Page 274 and 275:
Page 276 and 277:
Page 278 and 279:
Page 280 and 281:
W34 State-of-the-art of basic and c
Page 282 and 283:
Page 284 and 285:
Page 286 and 287:
Page 288 and 289:
Page 290 and 291:
Page 292 and 293:
Page 294 and 295:
W29 New horizons in therapeutic dru
Page 296 and 297:
Page 298 and 299:
Page 300 and 301:
Page 302 and 303:
Page 304 and 305:
Page 306 and 307:
Page 308 and 309:
Page 310 and 311:
Page 312 and 313:
Page 314 and 315:
Page 316 and 317:
314 Index Name Paper ref. Name Pape
Page 318 and 319:
Page 320 and 321:
Page 322 and 323:
Page 324 and 325:
Page 326 and 327:
Page 328 and 329:
Page 330 and 331:
Page 332 and 333: 330 Index Name Paper ref. Name Pape
Page 384 and 385: 382 Notes Notes
Page 386: Final Programme printed in Singapor
show all

Final Programme - iuphar

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?